ReviewNature reviews. Rheumatology2016
ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients.
Review in Nature reviews. Rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
134 citing papers in PubMed, 3 syntheses or guidelines pooled it, 289 citations in OpenAlex.
- Arterial Stiffness and Adult Onset Vasculitis: A Systematic Review.Frontiers in medicine · 2022Pooled it
- Incidence and risk factors of venous thromboembolism in ANCA-associated vasculitis: a metaanalysis and metaregression.Clinical rheumatology · 2021Pooled it
- Neutrophil Extracellular Traps (NETs) and Vasculitis.International journal of medical sciences · 2021Pooled it
- Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis.JCI insight · 2021Trial
- Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited.Clinical pharmacokinetics · 2020Trial
- Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.Frontiers in immunology · 2020Trial
- Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.Rheumatology (Oxford, England) · 2018Trial
- Therapeutic plasma exchange in paediatric ANCA-associated vasculitis: a multicentre real-world experience.Rheumatology (Oxford, England) · 2026Observational
- Identification of clinical-biological endophenotypes in patients with eosinophilic granulomatosis with polyangiitis using unsupervised machine learning: a real-world study.Respiratory research · 2026Observational
- Structures of proteinase 3 and the CD177 receptor complex reveal a major autoantibody epitope.EMBO reports · 2026Article
- Overlapping forms of granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis: Insights from a European multicenter study.Journal of internal medicine · 2026Observational
- Plasmablasts as Translational Biomarkers in Autoimmune Diseases: From Cellular Dynamics to Clinical Decision-Making.Current issues in molecular biology · 2026Review
- Clinical and electrodiagnostic features of nerve conduction study-classified peripheral neuropathy in symptomatic patients with antineutrophil cytoplasmic antibody-associated vasculitis: a single-centre cohort study.Frontiers in immunology · 2026Article
- Initial Circulating CD138 Predicts End-Stage Kidney Disease in Patients with Microscopic Polyangiitis.Yonsei medical journal · 2025Article
- Therapeutics controversies in antineutrophilic cytoplasmic antibody-associated vasculitis.Clinical and experimental nephrology · 2025Review
- Advances in the treatment of ANCA-associated vasculitis.Nature reviews. Rheumatology · 2025Review
- Article
- Simplifying ANCA-associated vasculitis classification with ANCA specificity: a retrospective analysis.Clinical rheumatology · 2025Article
- CCL23 is a potential biomarker for antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis research & therapy · 2025Article
- Targeted Complement Treatments in Glomerulopathies: A Comprehensive Review.Journal of clinical medicine · 2025Review
74 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a heterogeneous group of rare syndromes characterized by necrotizing inflammation of small and medium-sized blood vessels and the presence of ANCAs. Several clinicopathological classification systems exist that aim to define homogeneous groups among patients with AAV, the main syndromes being microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA) and eosinophilic GPA (EGPA). Two main types of ANCA can be detected in patients with AAV. These ANCAs are defined according to their autoantigen target, namely leukocyte proteinase 3 (PR3) and myeloperoxidase (MPO). Patients with GPA are predominantly PR3-ANCA-positive, whereas those with MPA are predominantly MPO-ANCA-positive, although ANCA specificity overlaps only partially with these clinical syndromes. Accumulating evidence suggests that ANCA specificity could be better than clinical diagnosis for defining homogeneous groups of patients, as PR3-ANCA and MPO-ANCA are associated with different genetic backgrounds and epidemiology. ANCA specificity affects the phenotype of clinical disease, as well as the patient's initial response to remission-inducing therapy, relapse risk and long-term prognosis. Thus, the classification of AAV by ANCA specificity rather than by clinical diagnosis could convey clinically useful information at the time of diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.